Loading...
•
Dec 31, 2020
Celsion Q4 2020 Earnings Report
Reported financial results for the year ended December 31, 2020 and provided an update on clinical development programs.
Key Takeaways
Celsion reported a net loss of $21.5 million ($0.67 per share) in 2020, compared with a net loss of $16.8 million ($0.77 per share) in 2019. The company is focusing on DNA-based immunotherapies and next-generation vaccines, supported by a strong balance sheet.
Focused on DNA-based immunotherapies for ovarian cancer and next-generation vaccines.
OVATION 2 Study is over one-third enrolled with 25 clinical sites expected to be activated by the end of Q1 2021.
Filed provisional U.S. patent application for a broad range of next-generation DNA vaccines.
Strengthened balance sheet through a $35 million registered direct offering of common shares.